Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

Slides:

Advertisements

Similar presentations

ASCOT Lancet, April 2003 n=10,305 Evidence for: primary prevention of CHD and stroke in high risk, middle aged, hypertensive, male patients with TC

Advertisements

The ABC’s of the AHA/ACC Prevention Guidelines

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.

Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Cardiovascular Risk Diabetes And Aspirin A Closer look into the evidence-base Howard Van IM2 Ahraaz Wyne IM1 The University of Western Ontario London Health.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risks of Progression of Retinopathy and Vision Loss.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.

Date of download: 6/26/2016 From: Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

Copyright © 2003 American Medical Association. All rights reserved.

Health and Human Services National Heart, Lung, and Blood Institute

Copyright © 2011 American Medical Association. All rights reserved.

Preventing Cardiovascular Disease

Nat. Rev. Cardiol. doi: /nrcardio

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Comprehensive Diabetes Care

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

اتجاهات أنماط المرض بين السكان. المراحل الأربع للتحول الوبائى.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Aspirin in Cardioprevention:

Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,

David J.A. Jenkins et al. JACC 2018;71:

Yousef Rezaei, MD American Journal of Kidney Diseases

Figure 1 Relationships between magnitude of antithrombotic benefit vs

Berger JS, et al. JAMA 2009;301:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Cardiovascular Disease in Women Module IX: Presentation Resources and Internet Resources This slide set was updated April 2008.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Health profile used in workshops to help people make diabetes management decisions. Health profile used in workshops to help people make diabetes management.

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

P-Care Personal health CARE for monitoring Cardiovascular Disease

Baseline predictors of acute complication of diabetes among immigrants with language barriers (N = 87,707). *Adjustment for all variables listed, as well.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Increase of physical activity over time associated with lower HF risk

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

Mean score of aberrant behavioral checklist: irritability at end of treatment in RCTs of atypical antipsychotics for the treatment of irritability in autism.

A: Probability of retinopathy-free survival.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

The risk for incident cognitive dysfunction after an episode of severe (A) or nonsevere (B) hypoglycemia with and without accounting for the competing.

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Presentation transcript:

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2=8.71, P=0.367, I2=8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2=11.0, P=0.20, I2=27.2%. CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians’ Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women’s Health Study. Michael Pignone et al. Dia Care 2010;33:1395-1402 ©2010 by American Diabetes Association